Novartis touts older cancer drug for MS in attack on Roche’s Ocrevus
ZURICH (Reuters) – Novartis said on Wednesday that an older leukaemia drug it is re-purposing for multiple sclerosis halted disease activity in many patients during the first two years of injections as the Swiss drugmaker...
Read More